Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

BioNTech (BNTX) is presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...